Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial)

American Journal of Cardiology - Tập 71 - Trang 909-915 - 1993
Uri Goldbourt1,2, Solomon Behar1,2, Henrietta Reicher-Reiss1,2, Jacob Agmon1,2, Elieser Kaplinsky1,2, Eran Graft1,2, Yehezkiel Kishon1,2, Avraham Caspi1,2, Joshua Weisbort1,2, Lori Mandelzweig1,2, Edward Abinader1,2, Leon Aharon1,2, Shimeon Braun1,2, Daniel David1,2, Michael Flich1,2, Yaacov Friedman1,2, Natalio Kristal1,2, Noa Leil1,2, Walter Markiewicz1,2, Alon Marmor1,2
1From the Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, Israel
2From the Edith Wolfson Medical Center, Holon, Israel

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

American Journal of Cardiology

Tập 71

909-915

Thông tin tác giả